Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Alimera Sciences Inc (ALIM)

Alimera Sciences Inc (ALIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 291,807
  • Shares Outstanding, K 52,389
  • Annual Sales, $ 80,750 K
  • Annual Income, $ -20,130 K
  • 60-Month Beta 1.28
  • Price/Sales 3.62
  • Price/Cash Flow N/A
  • Price/Book 7.19
Trade ALIM with:

Options Overview Details

View History
  • Implied Volatility 160.51% ( +15.11%)
  • Historical Volatility 163.53%
  • IV Percentile 75%
  • IV Rank 34.09%
  • IV High 436.20% on 02/26/24
  • IV Low 17.90% on 05/15/24
  • Put/Call Vol Ratio 3.00
  • Today's Volume 8
  • Volume Avg (30-Day) 271
  • Put/Call OI Ratio 8.25
  • Today's Open Interest 1,304
  • Open Int (30-Day) 3,149

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.03
  • Number of Estimates 1
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +93.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.51 +1.09%
on 06/26/24
5.65 -1.42%
on 06/24/24
+2.42 (+76.83%)
since 06/21/24
3-Month
2.77 +101.08%
on 06/10/24
5.65 -1.42%
on 06/24/24
+2.03 (+57.34%)
since 04/22/24
52-Week
2.61 +113.71%
on 10/16/23
5.65 -1.42%
on 06/24/24
+2.06 (+58.69%)
since 07/21/23

Most Recent Stories

More News
Alimera Sciences: Q1 Earnings Snapshot

Alimera Sciences: Q1 Earnings Snapshot

ALIM : 5.57 (+0.09%)
Alimera Sciences: Q4 Earnings Snapshot

Alimera Sciences: Q4 Earnings Snapshot

ALIM : 5.57 (+0.09%)
Alimera Sciences: Q3 Earnings Snapshot

Alimera Sciences: Q3 Earnings Snapshot

ALIM : 5.57 (+0.09%)
Alimera Sciences: Q2 Earnings Snapshot

Alimera Sciences: Q2 Earnings Snapshot

ALIM : 5.57 (+0.09%)
Alimera Sciences: Q1 Earnings Snapshot

Alimera Sciences: Q1 Earnings Snapshot

ALIM : 5.57 (+0.09%)
Alimera Sciences: Q4 Earnings Snapshot

Alimera Sciences: Q4 Earnings Snapshot

ALIM : 5.57 (+0.09%)
Alimera Sciences: Q3 Earnings Snapshot

Alimera Sciences: Q3 Earnings Snapshot

ALIM : 5.57 (+0.09%)
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...

ALIM : 5.57 (+0.09%)
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

Reimbursement granted with no restrictions to the labelAlimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences,...

ALIM : 5.57 (+0.09%)
Alimera Sciences Announces Second Quarter 2022 Financial Results

Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021U.S. End User Demand up 45% vs. Second Quarter of 2021International...

ALIM : 5.57 (+0.09%)

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

3rd Resistance Point 5.60
2nd Resistance Point 5.59
1st Resistance Point 5.58
Last Price 5.57
1st Support Level 5.56
2nd Support Level 5.55
3rd Support Level 5.54

See More

52-Week High 5.65
Last Price 5.57
Fibonacci 61.8% 4.49
Fibonacci 50% 4.13
Fibonacci 38.2% 3.77
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar